# Standardized Screening Template for Multi-Drug Resistant Tuberculosis: A Comprehensive Diagnostic Approach to Early Detection and Management

Ekedigwe John Ekene<sup>1</sup>; Ayara Charles Oshevire<sup>2</sup>; Onubi Jeremiah<sup>3</sup>; Elisha Adesegun<sup>4</sup>; Adeola Oluwagbenga<sup>5</sup>; Eseigbe Patricia<sup>6</sup>; Amaku Chiemezie U.<sup>7</sup>; Chima George. <sup>8</sup>

## Address for Correspondence:

Ekedigwe John Ekene, Department of Radiology, Bingham University, College of Medicine, Bingham University Teaching Hospital, Jos

Publication Date: 2025/03/11

Abstract: Multi-drug resistant tuberculosis (MDR-TB) remains a critical global health challenge, particularly in regions with limited healthcare resources. This study presents a novel, standardized screening template designed to improve the early detection, classification, and management of MDR-TB through a comprehensive, user-friendly diagnostic approach. The proposed framework integrates patient demographic data, systematic chest X-ray analysis, and drug resistance classification to enhance diagnostic precision and clinical decision-making. Preliminary evaluations suggest that this template offers significant potential for improving early MDR-TB detection, supporting global reporting, and enabling targeted interventions. Furthermore, the template's adaptability for digital conversion ensures relevance in both manual and technologically advanced settings, laying the groundwork for enhanced epidemiological tracking and public health interventions.

Keywords: Multi-Drug-Resistant Tuberculosis (MDR-TB), Radiological Patterns, Non - HIV Patients, Thoracic Compilation.

**How to Cite:** Ekedigwe John Ekene; Ayara Charles Oshevire; Onubi Jeremiah; Elisha Adesegun; Adeola Oluwagbenga; Eseigbe Patricia; Amaku Chiemezie U.; Chima George. (2025) Standardized Screening Template for Multi-Drug Resistant Tuberculosis: A Comprehensive Diagnostic Approach to Early Detection and Management. *International Journal of Innovative Science and Research Technology*, 10(2), 1938-1940. https://doi.org/10.5281/zenodo.14987415

## I. INTRODUCTION

Tuberculosis (TB) continues to be a significant global health threat, with multi-drug resistant strains posing an increasingly complex challenge to healthcare systems worldwide. According to the World Health Organization (WHO), approximately 500,000 new cases of rifampicinresistant TB emerge annually, many of which progress to

MDR-TB [1]. These resistant strains threaten global TB control efforts, as they require prolonged treatment regimens that are often less effective and more toxic than first-line therapies.

Nigeria bears a substantial burden of TB, ranking among the top 10 countries with the highest TB cases globally. The challenge is compounded by diagnostic gaps,

<sup>&</sup>lt;sup>1</sup> Department of Radiology, Bingham University, College of Medicine, Bingham University Teaching Hospital, Jos

<sup>&</sup>lt;sup>2</sup> Department of Chemical Pathology, Bingham University, College of Medicine, Bingham University Teaching Hospital, Jos,

<sup>&</sup>lt;sup>3</sup> Department of Medical Microbiology and Parasitology, Bingham University, College of Medicine, Bingham University Teaching Hospital, Jos,

<sup>&</sup>lt;sup>4</sup> Department of Family Medicine, Bingham University, College of Medicine, Bingham University Teaching Hospital, Jos

ISSN No:-2456-2165

https://doi.org/10.5281/zenodo.14987415

with many cases going undetected or diagnosed too late for effective management. Current diagnostic tools, while effective, are often inaccessible due to high costs, infrastructure limitations, and lack of trained personnel. Hence, a standardized, scalable screening approach is urgently needed to bridge these gaps.

This study introduces a standardized screening template aimed at addressing the gaps in current diagnostic practices for MDR-TB. By providing a comprehensive framework for early detection and classification, the proposed template seeks to enhance the accuracy and efficiency of TB management protocols, particularly in resource-constrained settings such as Nigeria.

#### II. METHODOLOGY

## A. Template Development

The development of the standardized screening template involved a multi-phase approach, including literature review, expert consultations, and iterative testing. Key design considerations were guided by WHO guidelines, national TB control protocols, and insights from frontline healthcare professionals. The final template integrates evidence-based parameters to support comprehensive and systematic data collection.

## B. Diagnostic Screening Framework

The framework integrates the following elements:

## ➤ Patient Demographics

Collection of age, gender, occupation, and exposure history to identify high-risk populations.

### ➤ Lung Zone Assessment:

Comprehensive analysis of chest X-ray findings, with emphasis on common MDR-TB indicators such as fibrotic lesions and extensive infiltrates.

## > Shadow Type Characterization:

Systematic documentation of radiographic abnormalities, including nodular opacities and pleural effusions.

### > Cavity Detection and Measurement:

Quantitative assessment of pulmonary cavities, including size, location, and wall thickness.

## ➤ Drug Resistance Classification:

A three-tier system categorizing MDR-TB status into confirmed, suspected, and not confirmed cases based on microbiological and clinical findings.

## C. Validation Process

The template was piloted in a tertiary healthcare facility in Nigeria. Data were collected from 200 patients undergoing evaluation for TB, with radiographic and microbiological findings used to validate the classification system. Following this initial validation, the template was applied to over 1,000 patient datasets, demonstrating a high success rate in accurately identifying MDR-TB cases.

Clinician feedback highlighted the template's usability and effectiveness in standardizing diagnostic practices.

## III. RESULTS AND TEMPLATE FUNCTIONALITY

## A. Standardized Data Collection

The proposed template addresses key limitations in current TB screening methods by:

- Establishing a uniform data collection protocol applicable across different levels of healthcare facilities.
- Enabling consistent documentation of diagnostic findings, reducing variability between clinicians.
- Supporting manual data entry while being easily adaptable for digital platforms, ensuring scalability in diverse healthcare settings.

## B. Multi-Drug Resistance Classification

The classification system facilitates:

- Rapid identification of confirmed MDR-TB cases using molecular diagnostic tools such as GeneXpert.
- Provisional diagnosis of suspected cases based on radiographic and clinical markers, guiding further investigations.
- Documentation of cases not meeting MDR-TB criteria, reducing unnecessary treatment interventions.

## C. Integration with Existing Systems

The template is designed for compatibility with Nigeria's existing National Tuberculosis and Leprosy Control Programme (NTBLCP). It supports integration into electronic health records (EHRs), enhancing data sharing and continuity of care.

## IV. DISCUSSION

## A. Clinical Significance

The screening template offers several advantages:

## ➤ Enhanced Early Detection:

By reducing diagnostic ambiguity, the template facilitates timely initiation of appropriate treatment, which is critical for improving patient outcomes.

## ➤ Comprehensive Patient Profiling:

The inclusion of detailed demographic and clinical data enables individualized treatment plans tailored to patient needs.

## ➤ Global Reporting Support:

The standardized format ensures consistency in data reporting, supporting international efforts to monitor and control MDR-TB.

## B. Technological Integration

Designed for digital conversion, the template supports spreadsheet compatibility, EHR integration, and epidemiological data analysis. This ensures adaptability across various healthcare infrastructures, from rural clinics to urban tertiary hospitals. The digital format also facilitates large-scale data aggregation, which is essential for public health research and policy development.

## C. Relevance to the Nigerian Context

Given Nigeria's high TB burden and limited resources, the template's simplicity and adaptability make it particularly suited to the local healthcare landscape. By addressing key diagnostic gaps, it has the potential to improve TB control efforts nationwide.

#### V. 5. LIMITATIONS AND FUTURE RESEARCH

While promising, the template has certain limitations:

#### ➤ Validation Scope:

The current validation study was conducted in a single healthcare facility. Multi-center studies are needed to establish broader applicability.

#### > Resource Constraints:

Implementation in resource-limited settings may face challenges such as inadequate infrastructure and workforce training.

## ➤ Evolving Clinical Evidence:

Continuous refinement is necessary to incorporate emerging diagnostic technologies and updates in clinical guidelines.

- Future Research should Focus on:
- Expanding validation studies to include diverse patient populations and healthcare settings.
- Assessing the cost-effectiveness of the template compared to existing diagnostic approaches.
- Exploring the integration of artificial intelligence (AI) to enhance the template's diagnostic capabilities.

## VI. CONCLUSION

The proposed standardized screening template represents a significant advancement in MDR-TB diagnostic methodology. By providing a comprehensive, user-friendly approach to early detection and management, it has the potential to improve patient outcomes, reduce transmission, and enhance global TB control efforts. Its relevance to the Nigerian healthcare context underscores its potential impact in high-burden settings, where early and accurate diagnosis is critical for effective disease control. The successful application of the template to over 1,000 patient datasets further validates its utility and underscores its potential to transform TB diagnostic practices.

### **ACKNOWLEDGMENTS**

Special thanks to healthcare professionals working on the frontlines of TB detection and treatment.

## > Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### ➤ Conflict of Interest

The authors declare no conflicts of interest.

#### REFERENCES

- [1]. World Health Organization. Global Tuberculosis Report 2023.
- [2]. Centers for Disease Control and Prevention. Multidrug-Resistant Tuberculosis (MDR TB) Diagnostic Guidelines.
- [3]. International Union Against Tuberculosis and Lung Disease. Clinical Management Protocols for Drug-Resistant Tuberculosis.
- [4]. Federal Ministry of Health, Nigeria. National Tuberculosis and Leprosy Control Programme Guidelines, 2021.